HomeBUSINESS
BUSINESS

Lonsurf Earns Priority Status in Canada: Taiho
(Oct.23.2017)

Taiho Pharmaceutical said on October 20 that its new drug application for its cancer drug TAS-102 (trifluridine + tipiracil) was accepted by Canada’s health authority for the treatment of refractory metastatic colorectal cancer, and granted a priority review status for the indication ...
(LOG IN FOR FULL STORY)

News Calendar